Details der Publikation - Clinical review report

Clinical review report : Letermovir (Prevymis) (Merck Canada Inc.)

According to the Health Canada-approved indication, letermovir can be used for the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Therefore, the objective of this review is to perform a systematic review of the beneficial and harmful effects of letermovir for the prophylaxis of CMV infection in adult CMV-seropositive recipients of an allogeneic HSCT..

Medienart:	E-Book

Erscheinungsjahr:	July 2018
Erschienen:	Ottawa (ON): Canadian Agency for Drugs and Technologies in Health ; July 2018

Reihe:	CADTH common drug review

Sprache:	Englisch

Links:	www.ncbi.nlm.nih.gov [teilw. kostenfrei]

Themen:	Acetates Antibiotic Prophylaxis Antiviral Agents Canada Cytomegalovirus Infections Hematopoietic Stem Cell Transplantation Quinazolines Systematic Review Tables

Anmerkungen:	"Version: Final.". - Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed June 10, 2019)

Umfang:	1 online resource (1 PDF file (93 pages)) ; illustrations.

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1773193457

Internformat


LEADER	01000cam a22002652 4500
001	1773193457
003	DE-627
005	20230428012011.0
007	cr uuu---uuuuu
008	211011s2018 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)1773193457
035			\|a (DE-599)KEP068702221
035			\|a (NCBI)9917472043406676
035			\|a (EBP)068702221
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
245	1	0	\|a Clinical review report \|b Letermovir (Prevymis) (Merck Canada Inc.)
264		1	\|a Ottawa (ON) \|b Canadian Agency for Drugs and Technologies in Health \|c July 2018
300			\|a 1 online resource (1 PDF file (93 pages)) \|b illustrations.
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
490	0		\|a CADTH common drug review
500			\|a "Version: Final.". - Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed June 10, 2019)
520			\|a According to the Health Canada-approved indication, letermovir can be used for the prophylaxis of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Therefore, the objective of this review is to perform a systematic review of the beneficial and harmful effects of letermovir for the prophylaxis of CMV infection in adult CMV-seropositive recipients of an allogeneic HSCT.
650		2	\|a Cytomegalovirus Infections \|x drug therapy \|0 https://id.nlm.nih.gov/mesh/D003586Q000188
650		2	\|a Acetates \|x therapeutic use \|0 https://id.nlm.nih.gov/mesh/D000085Q000627
650		2	\|a Antibiotic Prophylaxis \|x methods \|0 https://id.nlm.nih.gov/mesh/D019072Q000379
650		2	\|a Antiviral Agents \|x therapeutic use \|0 https://id.nlm.nih.gov/mesh/D000998Q000627
650		2	\|a Hematopoietic Stem Cell Transplantation \|0 https://id.nlm.nih.gov/mesh/D018380
650		2	\|a Quinazolines \|x therapeutic use \|0 https://id.nlm.nih.gov/mesh/D011799Q000627
651		2	\|a Canada \|0 https://id.nlm.nih.gov/mesh/D002170
655		2	\|a Systematic Review \|0 https://id.nlm.nih.gov/mesh/D000078182
655		2	\|a Tables \|0 https://id.nlm.nih.gov/mesh/D020501
710	2		\|a Canadian Agency for Drugs and Technologies in Health, \|e MitwirkendeR \|4 ctb
856	4	0	\|u https://www.ncbi.nlm.nih.gov/books/NBK539334/ \|m X:NCBI \|x Verlag \|z teilw. kostenfrei
912			\|a ZDB-193-NCB
912			\|a GBV_ILN_22
912			\|a ISIL_DE-18
912			\|a SYSFLAG_1
912			\|a GBV_KXP
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_22_i06404
912			\|a GBV_ILN_40
912			\|a ISIL_DE-7
912			\|a GBV_ILN_74
912			\|a ISIL_DE-354
912			\|a GBV_ILN_2003
912			\|a ISIL_DE-25
912			\|a GBV_ILN_2009
912			\|a ISIL_DE-180
912			\|a GBV_ILN_2010
912			\|a ISIL_DE-15
951			\|a BO
980			\|2 22 \|1 01 \|x 0018 \|b 3994090326 \|h h64 NCBI \|y zi06404 \|z 21-10-21
980			\|2 40 \|1 01 \|x 0007 \|b 3994016606 \|h OLR-NCB-BOOKSHELF \|y xsn \|z 21-10-21
980			\|2 74 \|1 01 \|x 0354 \|b 399979318X \|c 09 \|f E-Bibl \|d EM 0000 \|e --%%-- \|j --%%-- \|y ze \|z 08-11-21
980			\|2 2003 \|1 01 \|x DE-25 \|b 3995685919 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j n \|k Elektronischer Volltext - Open Access \|y l01 \|z 25-10-21
980			\|2 2009 \|1 01 \|x DE-180 \|b 3987683317 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j --%%-- \|y l01 \|z 11-10-21
980			\|2 2010 \|1 01 \|x DE-15 \|b 3987772565 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j n \|k Elektronischer Volltext - Open Access \|y l01 \|z 11-10-21
981			\|2 22 \|1 01 \|x 0018 \|r https://www.ncbi.nlm.nih.gov/books/NBK539334/
981			\|2 40 \|1 01 \|x 0007 \|y Volltext, Open Access \|r https://www.ncbi.nlm.nih.gov/books/NBK539334/
981			\|2 74 \|1 01 \|x 0354 \|r https://www.ncbi.nlm.nih.gov/books/NBK539334/
981			\|2 2003 \|1 01 \|x DE-25 \|r https://www.ncbi.nlm.nih.gov/books/NBK539334/
981			\|2 2010 \|1 01 \|x DE-15 \|y Online-Zugriff \|r https://www.ncbi.nlm.nih.gov/books/NBK539334/
985			\|2 22 \|1 01 \|x 0018 \|a h64 ebook
985			\|2 74 \|1 01 \|x 0354 \|a EM 0000
995			\|2 22 \|1 01 \|x 0018 \|a h64 NCBI
995			\|2 22 \|1 01 \|x 0018 \|a h64 freie Ressource
995			\|2 40 \|1 01 \|x 0007 \|a OLR-NCB-BOOKSHELF

Clinical review report : Letermovir (Prevymis) (Merck Canada Inc.)

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände